Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.
Transparent and comprehensive information is the foundation of our corporate communications. Current press releases and an archive of press releases to the year 2008 can be found here.
PAION AG reports financial results for the first half-year of 2017
PAION announces clinical development progress with remimazolam by its partner R-Pharm in Russia
PAION AG raises EUR 8.0 million in private placement
PAION AG: PAION reports positive headline data in U.S. Phase III trial with remimazolam for procedural sedation during bronchoscopy
PAION AG: Annual General Meeting approves all agenda items and elects Dr. Dr. Irina Antonijevic and Dr. Chris Tanner to the Supervisory Board
PAION reports positive headline data in U.S. clinical safety trial of remimazolam in high-risk patients undergoing colonoscopy
PAION successfully completes patient recruitment in U.S. Phase III study with remimazolam for procedural sedation during bronchoscopy
PAION AG reports on fiscal year and financial results 2016
PAION AG: Change in Management Board
PAION AG announces successful completion of capital increase with subscription rights
PAION AG: Capital increase; preliminary, unaudited key Group figures for 2016